Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DALE A PRESSER

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1922062512
CMS profile
703081
Location
COVINGTON, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,163.84

119 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,152.97 118
Education $10.87 1

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 119 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DALE A PRESSER

NPI 1922062512 · CMS profile ID 703081

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

COVINGTON, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 119 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1922062512?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DALE A PRESSER, NPI 1922062512, CMS profile ID 703081. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 119 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1922062512?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). DALE A PRESSER, NPI 1922062512, CMS profile ID 703081. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 119 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1922062512?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
DALE A PRESSER, NPI 1922062512, CMS profile ID 703081, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 119 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1922062512?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

119 matching records · $2,163.84 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 119 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 119.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Medtronic, Inc. $19.3908/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827332961 CMS
Novartis Pharmaceuticals Corporation $7.3607/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813173933 CMS
SANOFI-AVENTIS U.S. LLC $18.0307/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843536563 CMS
Medtronic, Inc. $8.8907/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827332927 CMS
E.R. Squibb & Sons, L.L.C. $20.7007/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783570967 CMS
Esperion Therapeutics, Inc. $9.1507/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838378505 CMS
Janssen Pharmaceuticals, Inc $12.1107/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788823555 CMS
Impulse Dynamics (USA) Inc. $19.0507/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843149981 CMS
Medtronic, Inc. $9.0707/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827332923 CMS
Medtronic, Inc. $2.9507/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827332925 CMS
Medtronic, Inc. $106.9107/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827332921 CMS
Novartis Pharmaceuticals Corporation $3.0107/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813173929 CMS
Merck Sharp & Dohme Corporation $15.6307/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848391779 CMS
Esperion Therapeutics, Inc. $21.1907/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838378503 CMS
Medtronic, Inc. $9.7707/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827332911 CMS
Novartis Pharmaceuticals Corporation $15.8406/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813173925 CMS
Kowa Pharmaceuticals America, Inc. $11.6206/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805556709 CMS
Medtronic, Inc. $7.9606/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827332979 CMS
E.R. Squibb & Sons, L.L.C. $14.0406/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783570825 CMS
Janssen Pharmaceuticals, Inc $15.0806/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788823549 CMS
Esperion Therapeutics, Inc. $11.2306/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838378497 CMS
Medtronic, Inc. $10.2605/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815767845 CMS
SANOFI-AVENTIS U.S. LLC $12.6105/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843536539 CMS
Janssen Pharmaceuticals, Inc $15.0805/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788823551 CMS
Novartis Pharmaceuticals Corporation $10.4805/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813173921 CMS
Medtronic, Inc. $27.2005/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815767829 CMS
Medtronic, Inc. $6.4405/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815767833 CMS
Medtronic, Inc. $67.5605/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815767837 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $11.7705/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763552298 CMS
Merck Sharp & Dohme Corporation $12.4805/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848558953 CMS
Medtronic, Inc. $26.0305/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827332985 CMS
Medtronic, Inc. $3.2605/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815766884 CMS
Kowa Pharmaceuticals America, Inc. $13.8605/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805556723 CMS
Janssen Pharmaceuticals, Inc $15.0804/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788823557 CMS
Medtronic, Inc. $21.6704/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815751251 CMS
Esperion Therapeutics, Inc. $14.3204/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838378493 CMS
Astellas Pharma US Inc $18.1604/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821500907 CMS
Medtronic, Inc. $4.6104/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815683887 CMS
Medtronic, Inc. $96.8204/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815751247 CMS
Novartis Pharmaceuticals Corporation $2.9304/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813173909 CMS
Amgen Inc. $12.3003/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825237301 CMS
E.R. Squibb & Sons, L.L.C. $18.5703/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783570801 CMS
Kowa Pharmaceuticals America, Inc. $13.9303/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805556719 CMS
Janssen Pharmaceuticals, Inc $15.0803/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788823553 CMS
Novartis Pharmaceuticals Corporation $12.1203/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813173917 CMS
Esperion Therapeutics, Inc. $14.7403/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838378489 CMS
Medtronic, Inc. $14.3903/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815692361 CMS
AstraZeneca Pharmaceuticals LP $11.5703/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829762189 CMS
Merck Sharp & Dohme Corporation $17.4303/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848515831 CMS
Amgen Inc. $11.4403/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825237297 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,505.52 122
PY2020 $1,905.63 88
PY2021 $2,163.84 119
PY2022 $2,308.93 93
PY2023 $3,640.71 78
PY2024 $1,112.21 38
PY2025 $1,125.87 34

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $586,176.10 16
PY2024 Principal investigator $473,977.45 8
PY2023 Principal investigator $340,473.78 8
PY2022 Principal investigator $220,214.85 2
PY2021 Principal investigator $81,060.98 1
PY2020 Principal investigator $11,924.40 1
PY2019 Principal investigator $6,718.58 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

16 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novartis Pharmaceuticals Corporation $285.89 11/15/2025 Non-covered Recipient Entity
STUDY GROUP
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190306733
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,000.00 09/23/2025 Non-covered Recipient Entity
CARDIOVASCULAR ASSOCIATES RESEARCH, LLC
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190309816
Principal investigator 1 Amgen Inc. $52,818.70 08/23/2025 Non-covered Recipient Entity
CARDIOVASCULAR ASSOCIATES RESEARCH LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246639997
Principal investigator 1 Novartis Pharmaceuticals Corporation $8,000.00 07/15/2025 Non-covered Recipient Entity
CARDIOVASCULAR ASSOCIATES RESEARCH
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C No dispute reported 06/30/2026 1190306151
Principal investigator 1 Novartis Pharmaceuticals Corporation $22,380.38 07/07/2025 Non-covered Recipient Entity
CARDIOVASCULAR ASSOCIATES RESEARCH, LLC
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C No dispute reported 06/30/2026 1190309820
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,000.00 06/24/2025 Non-covered Recipient Entity
CARDIOVASCULAR ASSOCIATES RESEARCH
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190306153
Principal investigator 1 Amgen Inc. $12,615.56 06/08/2025 Non-covered Recipient Entity
CARDIOVASCULAR ASSOCIATES RESEARCH, LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246639999
Principal investigator 1 Novartis Pharmaceuticals Corporation $24,191.37 05/27/2025 Non-covered Recipient Entity
CARDIOVASCULAR ASSOCIATES RESEARCH, LLC
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190309822
Principal investigator 1 Novartis Pharmaceuticals Corporation $21,555.40 01/30/2025 Non-covered Recipient Entity
CARDIOVASCULAR ASSOCIATES RESEARCH
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190306143
Principal investigator 1 Novartis Pharmaceuticals Corporation $60,911.27 01/17/2025 Non-covered Recipient Entity
CARDIOVASCULAR ASSOCIATES RESEARCH
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190306149
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,423.07 01/17/2025 Non-covered Recipient Entity
CARDIOVASCULAR ASSOCIATES RESEARCH, LLC
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190309818
Principal investigator 1 Novartis Pharmaceuticals Corporation $18,253.50 01/15/2025 Non-covered Recipient Entity
STUDY GROUP
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190306735
Principal investigator 1 Novartis Pharmaceuticals Corporation $62,073.00 01/07/2025 Non-covered Recipient Entity
CARDIOVASCULAR ASSOCIATES RESEARCH
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190306145
Principal investigator 1 Novartis Pharmaceuticals Corporation $19,874.09 01/07/2025 Non-covered Recipient Entity
CARDIOVASCULAR ASSOCIATES RESEARCH
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190306147
Principal investigator 1 Novartis Pharmaceuticals Corporation $65,902.86 01/02/2025 Non-covered Recipient Entity
CARDIOVASCULAR ASSOCIATES RESEARCH, LLC
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190309812
Principal investigator 1 Novartis Pharmaceuticals Corporation $194,891.01 01/02/2025 Non-covered Recipient Entity
CARDIOVASCULAR ASSOCIATES RESEARCH, LLC
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190309814